Entera Bio

Entera Bio EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Entera Bio (ENTX) as of Oct 8, 2026 is -72.09 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -102.08 % — a change of -29.38% (higher).

EBIT/Assets

-72.09 %

YoY

-29.38%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Entera Bio is 2025 -72.09 % . Operating Income to Assets Ratio (EBIT/Assets) of Entera Bio was 2024 -102.08 % . It decreases by -29.38% higher compared to the previous year.

The Entera Bio EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-81.41 USD
Jan 1, 2019
-68.57 USD
Jan 1, 2020
-114.51 USD
Jan 1, 2021
-47.01 USD
Jan 1, 2022
-99.16 USD
Jan 1, 2023
-75.99 USD
Jan 1, 2024
-102.08 USD
Jan 1, 2025
-72.09 USD
The Entera Bio EBIT/Assets history
YEAREBIT/AssetsYoY
-72.09 %-29.38%
-102.08 %+34.33%
-75.99 %-23.37%
-99.16 %+110.93%
-47.01 %-58.95%
-114.51 %+66.99%
-68.57 %-15.77%
-81.41 %-195.30%
85.43 %-200.05%
-85.38 %-36.63%
-134.73 %—
Access this data via the Eulerpool API

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Operating Income to Assets Ratio (EBIT/Assets) of Entera Bio is -72.09 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Entera Bio changed from -102.08 % to -72.09 %, representing a -29.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Entera Bio since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Entera Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

Profitability — Entera Bio

All Key Metrics — Entera Bio